Alkahest, Grifols deal

The companies partnered to develop plasma-based therapies to treat cognitive decline in aging and CNS disorders. Grifols will acquire a 45% stake in Alkahest for $37.5 million in cash and will receive worldwide commercialization rights to plasma-based CNS products. Alkahest will also receive an additional $12.5 million in research funding and is eligible for undisclosed milestones and royalties. ...